Valuation : Galapagos NV

Market Cap 160.24Cr 185.77Cr 150.73Cr 137.32Cr 258.23Cr 18TCr 259.63Cr 1.78TCr 693.58Cr 8.97TCr 697.46Cr 682.34Cr 30TCr P/E 2026 *
-13x
P/E 2027 * -6.59x
Enterprise Value -83Cr -96Cr -78Cr -71Cr -133.44Cr -9.11TCr -134.16Cr -920.8Cr -358.4Cr -4.63TCr -360.4Cr -352.59Cr -15TCr EV / Sales 2026 *
-8.73x
EV / Sales 2027 * 1.12x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 185.36Cr
+0.21%-2.69%+1.19%+17.32% 4.98TCr
+2.09%-0.71%+452.73%+498.77% 4.41TCr
-1.09%-0.41%+35.40%+15.17% 4.3TCr
-0.26%-4.71%+17.19%+71.67% 4.09TCr
-0.48%-0.84%+16.25%+49.80% 3.31TCr
-1.06%+2.87% - - 1.73TCr
-1.81%-5.02%+22.65%+113.24% 1.66TCr
-1.35%-3.40%+10.13%+26.34% 1.46TCr
-2.05%-5.14%+72.89%+34.69% 1.38TCr
Average -0.74%-2.11%+78.55%+103.38% 3.03TCr
Weighted average by Cap. -0.50%-1.88%+94.97%+120.43%

Financials

2026 *2027 *
Net sales 9.49Cr 11Cr 8.92Cr 8.13Cr 15Cr 1.04TCr 15Cr 105.49Cr 41Cr 530.93Cr 41Cr 40Cr 1.76TCr 8.03Cr 9.31Cr 7.55Cr 6.88Cr 13Cr 883.42Cr 13Cr 89Cr 35Cr 449.38Cr 35Cr 34Cr 1.49TCr
Net income -4.07Cr -4.72Cr -3.83Cr -3.49Cr -6.56Cr -447.75Cr -6.59Cr -45Cr -18Cr -227.76Cr -18Cr -17Cr -755.21Cr -21Cr -25Cr -20Cr -18Cr -34Cr -2.34TCr -34Cr -236.52Cr -92Cr -1.19TCr -93Cr -91Cr -3.95TCr
Net Debt -243.05Cr -281.76Cr -228.62Cr -208.28Cr -391.67Cr -27TCr -393.79Cr -2.7TCr -1.05TCr -14TCr -1.06TCr -1.03TCr -45TCr -151.23Cr -175.31Cr -142.25Cr -129.59Cr -243.7Cr -17TCr -245.02Cr -1.68TCr -654.55Cr -8.46TCr -658.22Cr -643.95Cr -28TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B